Metagenomi Therapeutics, Inc. (MGX)

Every figure this model derived for MGX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 309,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 120,664,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 124,468,000 AssetsCurrent 2026-06-30
current liabilities 27,632,000 LiabilitiesCurrent 2026-06-30
equity 112,567,000 StockholdersEquity 2026-06-30
ocf -85,487,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 22,331,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31
sbc 10,524,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up MGX on one particular measure came for.

RatioValue
cash operating margin-380.09
current ratio7.57
current ratio reported4.5
deferred revenue growth-40.88
dilution pct12.8
fcf margin-384.2
operating margin-450.34
owner earnings margin-431.33
revenue growth-50.66
revenue growth per share-56.26
rule of 40-501.01
sbc pct revenue47.13

What to be careful about

What this model itself distrusts about MGX's figures. Written by the derivation as it ran, not added afterwards.